H Zeng, J Castillo-Cabrera, M Manser, B Lu,
Z Yang… - Elife, 2019 - elifesciences.org
EGFR-mutant NSCLCs frequently respond to EGFR tyrosine kinase inhibitors (TKIs).
However, the responses are not durable, and the magnitude of tumor regression is variable …